File Download
Supplementary

Conference Paper: Nucleic Acid Aptamers Against Aggrecanases: A Novel Method for Degenerative Disc Disease Therapy

TitleNucleic Acid Aptamers Against Aggrecanases: A Novel Method for Degenerative Disc Disease Therapy
Authors
KeywordsAptamers
degenerative disc disease
ADAMTS-4
ADAMTS-5
SELEX
Issue Date2013
PublisherGlobal Biotechnology Congress.
Citation
Global Biotechnology Congress (GBC), Boston, USA, 3-6 June 2013. In the Abstract Book of the World Biotechnology Congress, 2013, p. 161, abstract no. PO-48 How to Cite?
AbstractAptamers are short, single-stranded oligonucleotides, which bind to their targets through 3D conformational complementarity. Aptamers are frequently called 'chemical antibodies' because of their high specificity and affinity. More than 20 aptamers for the treatment of various diseases are evaluated in clinical trials. Role of intervertebral disc is to absorb shock and transmit load, allowing the spine to bend and move. Disc degeneration may cause serious low back pain and affect daily life. Aggrecanases ADAMTS-4 and -5 are critical proteins involved in the development of degenerative disc disease (DDD) and osteoarthritis. They have been used as targets for inhibitor selection against DDD in recent studies both in vitro and in silico. Small molecules targeted on catalytic domain of aggrecanases have been developed but have broad inhibitory activity which may cause serious side effects. Nucleic acid aptamers can potentially solve this problem. Recent studies on aggrecanases have also been restrained by the low expression level and low solubility of the catalytic domain. Our studies have developed new ways to express, refold and purify human ADAMTS-4 and ADAMTS-5. ADAMTS-4 and ADAMTS-5 catalytic domain incorporating with disintegrin domain and thrombospondin motif are expressed and purified from E. coli with high yield for the first time. Specific aptamers will then be tailor selected against each aggrecanase through a process called Systematic Evolution of Ligands by Exponential enrichment (SELEX). Selected aptamers will then be characterized and evaluated as a foundation for further DDD therapeutic development.
DescriptionPoster presentation
Track: Pharmaceutical Biotechnology
Persistent Identifierhttp://hdl.handle.net/10722/186628

 

DC FieldValueLanguage
dc.contributor.authorYu, Yen_US
dc.contributor.authorTanner, JAen_US
dc.date.accessioned2013-08-20T12:15:37Z-
dc.date.available2013-08-20T12:15:37Z-
dc.date.issued2013en_US
dc.identifier.citationGlobal Biotechnology Congress (GBC), Boston, USA, 3-6 June 2013. In the Abstract Book of the World Biotechnology Congress, 2013, p. 161, abstract no. PO-48en_US
dc.identifier.urihttp://hdl.handle.net/10722/186628-
dc.descriptionPoster presentation-
dc.descriptionTrack: Pharmaceutical Biotechnology-
dc.description.abstractAptamers are short, single-stranded oligonucleotides, which bind to their targets through 3D conformational complementarity. Aptamers are frequently called 'chemical antibodies' because of their high specificity and affinity. More than 20 aptamers for the treatment of various diseases are evaluated in clinical trials. Role of intervertebral disc is to absorb shock and transmit load, allowing the spine to bend and move. Disc degeneration may cause serious low back pain and affect daily life. Aggrecanases ADAMTS-4 and -5 are critical proteins involved in the development of degenerative disc disease (DDD) and osteoarthritis. They have been used as targets for inhibitor selection against DDD in recent studies both in vitro and in silico. Small molecules targeted on catalytic domain of aggrecanases have been developed but have broad inhibitory activity which may cause serious side effects. Nucleic acid aptamers can potentially solve this problem. Recent studies on aggrecanases have also been restrained by the low expression level and low solubility of the catalytic domain. Our studies have developed new ways to express, refold and purify human ADAMTS-4 and ADAMTS-5. ADAMTS-4 and ADAMTS-5 catalytic domain incorporating with disintegrin domain and thrombospondin motif are expressed and purified from E. coli with high yield for the first time. Specific aptamers will then be tailor selected against each aggrecanase through a process called Systematic Evolution of Ligands by Exponential enrichment (SELEX). Selected aptamers will then be characterized and evaluated as a foundation for further DDD therapeutic development.-
dc.languageengen_US
dc.publisherGlobal Biotechnology Congress.-
dc.relation.ispartofGlobal Biotechnology Congressen_US
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectAptamers-
dc.subjectdegenerative disc disease-
dc.subjectADAMTS-4-
dc.subjectADAMTS-5-
dc.subjectSELEX-
dc.titleNucleic Acid Aptamers Against Aggrecanases: A Novel Method for Degenerative Disc Disease Therapyen_US
dc.typeConference_Paperen_US
dc.identifier.emailTanner, JA: jatanner@hku.hken_US
dc.identifier.authorityTanner, JA=rp00495en_US
dc.description.naturepublished_or_final_version-
dc.identifier.hkuros217917en_US
dc.identifier.spage161, abstract no. PO-48-
dc.identifier.epage161, abstract no. PO-48-
dc.publisher.placeUSA-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats